Beyond cancer: CAR-T cells redefining liver disease therapy
Abstract
Hepatic fibrosis remains a major unmet clinical challenge worldwide. Liver diseases can arise from a variety of etiologies with overlapping yet distinct pathogenic pathways. These etiologies include metabolic dysfunction-associated steatohepatitis (MASH), chronic viral hepatitis particularly hepatitis B and C, alcohol-associated liver disease (ALD), autoimmune diseases, biliary diseases, and drug-induced liver injury (1). Repeated or sustained hepatic injury from these insults drives fibrosis progression, which can culminate in cirrhosis—a late-stage condition characterized by extensive scarring, regenerative nodules, and loss of normal liver function—and may ultimately predispose to hepatocellular carcinoma (HCC).
Fields of Study & Subjects
Liver physiology and pathology
CAR-T cell therapy research
Liver Disease Diagnosis and Treatment
Publication details
- Journal / source
- JHEP Reports
- Volume
- 8
- Issue
- 5
- Pages
- 101808–101808
- Publication date
- 1 March 2026
- Language
- EN